ClinicalTrials.gg
CompletedNCT01736683Updated Oct 24, 2022Results posted

Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)

A Phase 2 interventional study of Sotatercept in Anemia, Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia, sponsored by Merck Sharp & Dohme LLC. Completed at 20 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-24.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 464 studies in Anemia with a site in United States — 38 open to participants now, 58 under way, 18 of them phase 3. Anemia · United States.

Enrollment
196th of 395
74 · median 72
Started
2012
with 24 others
Phase 2
109 of 464
9 open now
Registered
222nd of 464
by date

Among the 464 studies in Anemia with a site in United States, this one is the 196th largest by enrollment of the 395 interventional ones that give a count, is one of 25 that started in 2012, is one of 109 in phase 2, and was the 222nd registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

38 of the 464 studies in Anemia with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 464 studies in Anemia with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to determine a safe, tolerable and effective dose of sotatercept that results in the greatest frequency of improvement of anemia in patients diagnosed with low- or intermediate-1 risk myelodysplastic syndromes (MDS) or non-proliferative chronic myelomonocytic leukemia (CMML).

03

Conditions studied

  • Anemia
  • Myelodysplastic Syndromes
  • Chronic Myelomonocytic Leukemia
  • Low to Intermediate-1 MDS
  • Myelodysplastic Syndromes (MDS)
  • Chronic Myelomonocytic Leukemia (CMML)

Keywords

  • ACE-011
  • anemia
  • dose-ranging
  • intermediate-1 risk myelodysplastic syndromes
  • low risk myelodysplastic syndromes (MDS)
  • multicenter
  • open-label
  • parallel
  • phase 2
  • randomized
  • Sotatercept
  • Non-proliferative chronic myelomonocytic leukemia (CMML)
  • hemoglobin
  • transfusions
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women ≥ 18 years of age
  • Documented diagnosis of myelodysplastic syndromes (MDS) or non-proliferative chronic myelomonocytic leukemia (CMML), white blood cells (WBC) ≤ 13,000 /mm\^3, World Health Organization (WHO) that meets International Prognostic Scoring System (IPSS) criteria for low or intermediate-1 risk disease
  • Anemia, (Hgb) ≤ 9.0 g/dL or ≥ 2 units of Red Blood Cells (RBCs) within 84 days
  • No response or loss of response to Erythropoiesis-Stimulating Agents (ESAs) or erythropoetin (EPO) > 500 mU/ml
  • Eastern Cooperative Group () score ≤2.
  • Creatinine \< 1.5 * (ULN)
  • Total ≤3.0 mg/dL
  • (AST)/Serum glutamic oxaloacetic transaminase (SGOT) \& Alanine Aminotransferase (ALT)/Serum Glutamic Pyruvic (SGPT) ≤3.0 * Upper Limit of Norma (ULN)
  • Free of (other than MDS) for ≥2 years
  • Highly effective methods of for females and males

Exclusion criteria

Exclusion Criteria:

  • Chromosome 5q deletion
  • Pregnant or breast feeding women and males who do not agree to use condom during the sexual contact with females of
  • Major surgery within 30 days
  • Incomplete recovery or incomplete healing of wounds from previous surgery
  • Heart failure ≥3 ( (NYHA))
  • Thromboembolic or myocardial infarction event within 6 months
  • Concurrent anti-cancer cytotoxic chemotherapy
  • History of severe allergic or anaphylactic reaction or to recombinant protein
  • Known positive for Human Immunovirus () or infectious Hepatitis type C or active infectious Hepatitis type B
  • anemia unrelated to MDS
  • Thrombocytopenia (\<30,000/uL)
  • Uncontrolled hypertension
  • Treatment with another drug or device within 28 days prior to Day 1
  • Prior exposure to sotatercept (ACE-011)
  • Any serious medical condition, lab abnormality or psychiatric illness
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    Sotatercept 0.1 mg/kg

    Sotatercept 0.1 mg/kg

    Drug: Sotatercept

  • Experimental
    Sotatercept 0.3 mg/kg

    Sotatercept 0.3 mg/kg

    Drug: Sotatercept

  • Experimental
    Sotatercept 0.5 mg/kg

    Sotatercept 0.5 mg/kg

    Drug: Sotatercept

  • Experimental
    Sotatercept 1.0 mg/kg

    Sotatercept 1.0 mg/kg

    Drug: Sotatercept

  • Experimental
    Sotatercept 1.5 mg/kg

    Sotatercept 1.5 mg/kg

    Drug: Sotatercept

  • Experimental
    Sotatercept 2.0 mg/kg

    Sotatercept 2.0 mg/kg

    Drug: Sotatercept

Interventions

  • Sotatercept is supplied as a lyophilized powder that is reconstituted using Water for Injection (WFI) and administered as a subcutaneous injection (SC) injection by the study staff at the clinical site.

    Also known as: ACE-011, ActRIIA-IgG1Fc

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Erythroid Hematological Improvement (HI-E) Starting Before the Completion of Five Cycles of Treatment (Responder Rate)

    The responder rate includes non-transfusion dependent efficacy (NTDE) participants and transfusion dependent efficacy (TDE) participants. For non-transfusion dependence efficacy (NTDE) participants who required \< 4 units of RBCs in the 8 weeks prior to start of therapy, HI-E was defined as an increase of \>=1.5 g/dL hemoglobin sustained for 56 days over a period of \>=8 weeks. For transfusion dependence efficacy (TDE) participants who required \>=4 units of RBCs in the 8 weeks prior to start of therapy, HI-E was defined as a decrease of \>= 4 units of RBCs transfused sustained for 56 days over a period of 8 weeks.

    Time frame: Day 2 to Day 142

Secondary outcomes

  1. Time to Erythroid Hematological Improvement (HI-E) Response

    Time to first response = start date of first response (HI-E) - first dose date + 1 day. For NTDE participants (who required \< 4 units of RBCs in the 8 weeks prior to start of therapy), HI-E was defined as an increase of \>=1.5 g/dL hemoglobin sustained for 56 days over a period of \>=8 weeks. For TDE participants (who required \>=4 units of RBCs in the 8 weeks prior to start of therapy), HI-E was defined as a decrease of \>= 4 units of RBCs transfused sustained for 56 days over a period of 8 weeks.

    Time frame: Day 1 to Day 87

  2. Duration of Erythroid Hematological Improvement (HI-E)

    The duration of HI-E response for participants who responded was (the last date of the consecutive hemoglobin \[Hgb\] measurements of the first \>=56 day interval) - (the first date of the consecutive Hgb measurements of the first \>=56 day interval) + 1 day.

    Time frame: Day 1 to 183.7 weeks

  3. Time to Progression to Acute Myeloid Leukemia (AML) for Participants Who Had Progression

    Progression to AML used criteria by the International Working Group (IWG) Response Criteria in Myelodysplasia (Cheson, 2006). Progression is considered if any of the following are met: - \>=50% increase in blasts - \>=50% decrement from maximum remission/response levels in granulocytes or platelets - Reduction in Hgb concentration by \>=2 g/dL - Transfusion dependence This outcome was defined as a Kaplan-Meier estimate however few participants progressed so a Kaplan-Meier analysis could not be performed. Disclosed are time to progression values only for participants who did progress to AML.

    Time frame: Day 1 to 183.7 weeks

  4. Time to Progression to Events of Higher Risk Myelodysplastic Syndromes (MDS) Using the International Prognostic Scoring System (IPSS) For Participants Who Had Progression

    Progression to events of higher risk MDS used criteria from the International Prognostic Scoring System for MDS (IPSS) which assigns a prognostic score (0=good and increasing in risk by half-grades with the top score outlined below) for three prognostic variables: - Marrow blasts (score 0-2.0) - Karyotype (score 0-1.0) - Cytopenias: neutrophil, platelets, and Hg counts (score 0-0.5) The three individual scores are summed resulting in a full range of 0- 3.5 and placed into risk categories 0 = low risk 0.5-1.0 = intermediate-1 risk 1.5-2.0 = intermediate-2 risk \>=2.5 = high risk This outcome was defined as a Kaplan-Meier estimate however few participants progressed so a Kaplan-Meier analysis could not be performed. Data reported represent event times (weeks) for participants who did progress to higher risk MDS categories.

    Time frame: Day 1 to 257.3 weeks

  5. Kaplan-Meier Estimates for Progression-free Survival

    Participants who had disease progression were considered to have events. Participants who died without acute myeloid leukemia (AML) were also considered to have events with the event date as the date of death. Those who did not have disease progression and who were lost to follow-up were censored at the last known disease progression assessment date. Participants without disease progression at the last follow-up contact were censored at the date of the last follow-up contact date. Disease Progression to AML used criteria by the International Working Group (IWG) Response Criteria in Myelodysplasia (Cheson, 2006). Progression is considered if any of the following are met: - \>=50% increase in blasts - \>=50% decrement from maximum remission/response levels in granulocytes or platelets - Reduction in hemoglobin (Hgb) concentration by \>=2 g/dL - Transfusion dependence

    Time frame: Day 1 to 257.3 weeks

  6. Kaplan-Meier Estimates for Overall Survival (OS)

    OS was defined as the time between start of treatment and the death/censored date. Participants who died (regardless of the cause of death) were considered to have an event. Participants who were alive at the end of the study, and participants who were lost to follow-up, were censored at the last date when subjects were known to be alive.

    Time frame: Day 1 to 257.3 weeks

  7. Pharmacokinetic Parameters of Sotatercept: Serum Concentration at Various Study Timepoints

    Maximum observed serum concentration, obtained directly from the observed concentration versus time data.

    Time frame: Cycle 1 Day 8 and !5 up to Cycle 2 Day 1

  8. Participants With Treatment-Emergent Adverse Events (TEAE)

    An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. Treatment-emergent adverse events (TEAEs) are defined as any AE occurring or worsening on or after the first treatment of the study medication and within 42 days after the last dose. The severity of AEs was graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.0 and the scale: Grade 1 = Mild Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life threatening Grade 5 = Death. Relation to study drug was determined by the investigator. A treatment-related TEAE is defined as TEAE which was considered to be related to the study drug and reported as 'Suspected' on the CRF. AEs with a missing relationship were treated as 'treatment-related' in data summaries.

    Time frame: Day 1 up to 59.2 months

  9. Dose Limiting Toxicities (DLTs)

    The following were DLTs if the investigator suspected they were treatment related: 1. Increase to \>= 140 mmHg systolic blood pressure 2. Increase to \>=90 mmHg diastolic blood pressure 3. Increase to \>=140 systolic and increase \> 20 mmHg compared to baseline systolic 4. Increase to \>=90 mmHg diastolic and increase \> 20 mmHg compared to baseline diastolic 5. Introduction of new anti-hypertension medication during treatment 6. Increase in dose of baseline anti-hypertension medication during treatment 7. \>= Grade 2 (moderate severity or worse) hypertension as an adverse event

    Time frame: Day 1 to 59.2 months

  10. Number of Participants Who Achieved Red Blood Cell (RBC)-Transfusion Independence During the Erythroid Hematological Improvement (HI-E) Interval

    Number of participants who achieved RBC-independence was defined as participants who required no RBC-transfusions during a 56-day interval of erythroid hematological improvement (HI-E). NTDE = non-transfusion dependence efficacy participants who required \< 4 units of RBCs in the 8 weeks prior to start of therapy TDE = transfusion dependence efficacy participants who required \>=4 units of RBCs in the 8 weeks prior to start of therapy

    Time frame: Day 2 to Day 142

07

Results

Posted Jun 13, 2019

Participant flow

Participants were stratified by concentration of serum erythropoietin (EPO) (\<500 versus ≥500 IU/L), by number of transfusions within 56 days of study enrollment (\<4 versus ≥4 units of red blood cells) and assigned randomly to 0.1 mg/kg and 0.3 mg/kg arms.

Participant flow — Overall Study
MilestoneSotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgSotatercept 1.0 mg/kgSotatercept 2.0 mg/kg
Started7621355
Completed00000
Not completed7621355
Withdrew: Disease relapse00210
Withdrew: Adverse event02232
Withdrew: Withdrawal by subject00311
Withdrew: Lack of therapeutic effect7413201
Withdrew: Progressive disease00010
Withdrew: Other00191

Outcome measures

PrimaryPercentage of Participants With Erythroid Hematological Improvement (HI-E) Starting Before the Completion of Five Cycles of Treatment (Responder Rate)

The responder rate includes non-transfusion dependent efficacy (NTDE) participants and transfusion dependent efficacy (TDE) participants. For non-transfusion dependence efficacy (NTDE) participants who required \< 4 units of RBCs in the 8 weeks prior to start of therapy, HI-E was defined as an increase of \>=1.5 g/dL hemoglobin sustained for 56 days over a period of \>=8 weeks. For transfusion dependence efficacy (TDE) participants who required \>=4 units of RBCs in the 8 weeks prior to start of therapy, HI-E was defined as a decrease of \>= 4 units of RBCs transfused sustained for 56 days over a period of 8 weeks.

Time frame:
Day 2 to Day 142
Reported as:
Number · percentage of participants
Percentage of Participants With Erythroid Hematological Improvement (HI-E) Starting Before the Completion of Five Cycles of Treatment (Responder Rate)
percentage of participantsSotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgSotatercept 1.0 mg/kgSotatercept 2.0 mg/kg
All participants066.742.960.040.0
NTDE subpopulation——33.362.5100
TDE subpopulation066.744.459.325.0
SecondaryTime to Erythroid Hematological Improvement (HI-E) Response

Time to first response = start date of first response (HI-E) - first dose date + 1 day. For NTDE participants (who required \< 4 units of RBCs in the 8 weeks prior to start of therapy), HI-E was defined as an increase of \>=1.5 g/dL hemoglobin sustained for 56 days over a period of \>=8 weeks. For TDE participants (who required \>=4 units of RBCs in the 8 weeks prior to start of therapy), HI-E was defined as a decrease of \>= 4 units of RBCs transfused sustained for 56 days over a period of 8 weeks.

Time frame:
Day 1 to Day 87
Reported as:
Median · days
Time to Erythroid Hematological Improvement (HI-E) Response
daysSotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgSotatercept 1.0 mg/kgSotatercept 2.0 mg/kg
All participants—24.0 (2 to 44)1.0 (1 to 2)1.0 (1 to 86)48 (9 to 87)
NTDE subpopulation——1.0 (1 to 1)1.0 (1 to 52)9.0 (9 to 9)
TDE subpopulation—24.0 (2 to 44)1.5 (1 to 2)1.5 (1 to 86)87 (87 to 87)
SecondaryDuration of Erythroid Hematological Improvement (HI-E)

The duration of HI-E response for participants who responded was (the last date of the consecutive hemoglobin \[Hgb\] measurements of the first \>=56 day interval) - (the first date of the consecutive Hgb measurements of the first \>=56 day interval) + 1 day.

Time frame:
Day 1 to 183.7 weeks
Reported as:
Median · days
Duration of Erythroid Hematological Improvement (HI-E)
daysSotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgSotatercept 1.0 mg/kgSotatercept 2.0 mg/kg
All participants—62.5 (62 to 69)104.0 (56 to 1794)133.0 (58 to 1554)96.0 (58 to 134)
NTDE subpopulation——79.0 (79 to 79)1043.0 (69 to 1554)134.0 (134 to 134)
TDE subpopulation—62.5 (62 to 69)105.5 (56 to 1794)96.5 (58 to 1033)58.0 (58 to 58)
SecondaryTime to Progression to Acute Myeloid Leukemia (AML) for Participants Who Had Progression

Progression to AML used criteria by the International Working Group (IWG) Response Criteria in Myelodysplasia (Cheson, 2006). Progression is considered if any of the following are met: - \>=50% increase in blasts - \>=50% decrement from maximum remission/response levels in granulocytes or platelets - Reduction in Hgb concentration by \>=2 g/dL - Transfusion dependence This outcome was defined as a Kaplan-Meier estimate however few participants progressed so a Kaplan-Meier analysis could not be performed. Disclosed are time to progression values only for participants who did progress to AML.

Time frame:
Day 1 to 183.7 weeks
Reported as:
Number · weeks
Time to Progression to Acute Myeloid Leukemia (AML) for Participants Who Had Progression
weeksSotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgSotatercept 1.0 mg/kgSotatercept 2.0 mg/kg
Time to Progression to Acute Myeloid Leukemia (AML) for Participants Who Had Progression——45.678.0—
SecondaryTime to Progression to Events of Higher Risk Myelodysplastic Syndromes (MDS) Using the International Prognostic Scoring System (IPSS) For Participants Who Had Progression

Progression to events of higher risk MDS used criteria from the International Prognostic Scoring System for MDS (IPSS) which assigns a prognostic score (0=good and increasing in risk by half-grades with the top score outlined below) for three prognostic variables: - Marrow blasts (score 0-2.0) - Karyotype (score 0-1.0) - Cytopenias: neutrophil, platelets, and Hg counts (score 0-0.5) The three individual scores are summed resulting in a full range of 0- 3.5 and placed into risk categories 0 = low risk 0.5-1.0 = intermediate-1 risk 1.5-2.0 = intermediate-2 risk \>=2.5 = high risk This outcome was defined as a Kaplan-Meier estimate however few participants progressed so a Kaplan-Meier analysis could not be performed. Data reported represent event times (weeks) for participants who did progress to higher risk MDS categories.

Time frame:
Day 1 to 257.3 weeks
Reported as:
Number · weeks
Time to Progression to Events of Higher Risk Myelodysplastic Syndromes (MDS) Using the International Prognostic Scoring System (IPSS) For Participants Who Had Progression
weeksSotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgSotatercept 1.0 mg/kgSotatercept 2.0 mg/kg
Time to Progression to Events of Higher Risk Myelodysplastic Syndromes (MDS) Using the International Prognostic Scoring System (IPSS) For Participants Who Had Progression15.1—24.767.4—
SecondaryKaplan-Meier Estimates for Progression-free Survival

Participants who had disease progression were considered to have events. Participants who died without acute myeloid leukemia (AML) were also considered to have events with the event date as the date of death. Those who did not have disease progression and who were lost to follow-up were censored at the last known disease progression assessment date. Participants without disease progression at the last follow-up contact were censored at the date of the last follow-up contact date. Disease Progression to AML used criteria by the International Working Group (IWG) Response Criteria in Myelodysplasia (Cheson, 2006). Progression is considered if any of the following are met: - \>=50% increase in blasts - \>=50% decrement from maximum remission/response levels in granulocytes or platelets - Reduction in hemoglobin (Hgb) concentration by \>=2 g/dL - Transfusion dependence

Time frame:
Day 1 to 257.3 weeks
Reported as:
Median · weeks
Kaplan-Meier Estimates for Progression-free Survival
weeksSotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgSotatercept 1.0 mg/kgSotatercept 2.0 mg/kg
Kaplan-Meier Estimates for Progression-free Survival82.7 (15.1 to 82.7)NA (91.1 to NA)NA (58.6 to NA)NA (NA to NA)NA (79.9 to NA)
SecondaryKaplan-Meier Estimates for Overall Survival (OS)

OS was defined as the time between start of treatment and the death/censored date. Participants who died (regardless of the cause of death) were considered to have an event. Participants who were alive at the end of the study, and participants who were lost to follow-up, were censored at the last date when subjects were known to be alive.

Time frame:
Day 1 to 257.3 weeks
Reported as:
Median · weeks
Kaplan-Meier Estimates for Overall Survival (OS)
weeksSotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgSotatercept 1.0 mg/kgSotatercept 2.0 mg/kg
Kaplan-Meier Estimates for Overall Survival (OS)82.7 (NA to NA)NA (91.00 to NA)NA (58.6 to NA)NA (NA to NA)NA (79.1 to NA)
SecondaryPharmacokinetic Parameters of Sotatercept: Serum Concentration at Various Study Timepoints

Maximum observed serum concentration, obtained directly from the observed concentration versus time data.

Time frame:
Cycle 1 Day 8 and !5 up to Cycle 2 Day 1
Reported as:
Geometric mean · ng/mL
Pharmacokinetic Parameters of Sotatercept: Serum Concentration at Various Study Timepoints
ng/mLSotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgSotatercept 1.0 mg/kgSotatercept 2.0 mg/kg
Cycle 1 Day 8288.06 ± 70.941426.00 ± 27.762237.46 ± 40.776525.37 ± 28.3112886.14 ± 30.47
Cycle 1 Day 15240.31 ± 75.321207.68 ± 16.141869.52 ± 36.975149.74 ± 36.048303.73 ± 43.57
Cycle 2 Day 1252.20 ± 28.43957.58 ± 18.631323.91 ± 44.403467.58 ± 57.065329.63 ± 38.27
SecondaryParticipants With Treatment-Emergent Adverse Events (TEAE)

An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. Treatment-emergent adverse events (TEAEs) are defined as any AE occurring or worsening on or after the first treatment of the study medication and within 42 days after the last dose. The severity of AEs was graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.0 and the scale: Grade 1 = Mild Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life threatening Grade 5 = Death. Relation to study drug was determined by the investigator. A treatment-related TEAE is defined as TEAE which was considered to be related to the study drug and reported as 'Suspected' on the CRF. AEs with a missing relationship were treated as 'treatment-related' in data summaries.

Time frame:
Day 1 up to 59.2 months
Reported as:
Count of participants · Participants
Participants With Treatment-Emergent Adverse Events (TEAE)
ParticipantsSotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgSotatercept 1.0 mg/kgSotatercept 2.0 mg/kg
>= 1 Treatment-emergent adverse event (TEAE)6420345
>=1 Treatment-related TEAE237184
>=1 Serious TEAE126102
>=1 Serious TEAE related to treatment00001
>=1 TEAE severity 3 or 4129132
>=1 TEAE severity grade 3/4 related to treatment00101
>=1 TEAE leading to death01000
>=1 TEAE leading to dose reduction00000
>=1 TEAE leading to dose interruption01291
>=1 TEAE leading to dose interruption + reduction00010
>= 1 TEAE leading to drug discontinuation02232
SecondaryDose Limiting Toxicities (DLTs)

The following were DLTs if the investigator suspected they were treatment related: 1. Increase to \>= 140 mmHg systolic blood pressure 2. Increase to \>=90 mmHg diastolic blood pressure 3. Increase to \>=140 systolic and increase \> 20 mmHg compared to baseline systolic 4. Increase to \>=90 mmHg diastolic and increase \> 20 mmHg compared to baseline diastolic 5. Introduction of new anti-hypertension medication during treatment 6. Increase in dose of baseline anti-hypertension medication during treatment 7. \>= Grade 2 (moderate severity or worse) hypertension as an adverse event

Time frame:
Day 1 to 59.2 months
Reported as:
Count of participants · Participants
Dose Limiting Toxicities (DLTs)
ParticipantsSotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgSotatercept 1.0 mg/kgSotatercept 2.0 mg/kg
1. Increase to >= 140 mmHg systolic118192
2. Increase to >=90 mmHg diastolic00221
3. =140 systolic and increase > 20 mmHg base015102
4. >=90 mmHg diastolic and increase > 20 mmHg base00221
5. Introduction of new anti-hypertension med00431
6. Incre in dose of baseline anti-hypertension med00000
7.>= Grade 2 hypertension TEAE01241
SecondaryNumber of Participants Who Achieved Red Blood Cell (RBC)-Transfusion Independence During the Erythroid Hematological Improvement (HI-E) Interval

Number of participants who achieved RBC-independence was defined as participants who required no RBC-transfusions during a 56-day interval of erythroid hematological improvement (HI-E). NTDE = non-transfusion dependence efficacy participants who required \< 4 units of RBCs in the 8 weeks prior to start of therapy TDE = transfusion dependence efficacy participants who required \>=4 units of RBCs in the 8 weeks prior to start of therapy

Time frame:
Day 2 to Day 142
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Red Blood Cell (RBC)-Transfusion Independence During the Erythroid Hematological Improvement (HI-E) Interval
ParticipantsSotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgSotatercept 1.0 mg/kgSotatercept 2.0 mg/kg
All participants013151
NTDE subpopulation——161
TDE subpopulation01290

Adverse events

Collected over Day 1 up to 60.7 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sotatercept 0.1 mg/kg1/7 (14.3%)1/7 (14.3%)6/7 (85.7%)
Sotatercept 0.3 mg/kg1/6 (16.7%)2/6 (33.3%)4/6 (66.7%)
Sotatercept 0.5 mg/kg6/21 (28.6%)6/21 (28.6%)18/21 (85.7%)
Sotatercept 1.0 mg/kg6/35 (17.1%)10/35 (28.6%)32/35 (91.4%)
Sotatercept 2.0 mg/kg1/5 (20%)2/5 (40%)5/5 (100%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventSotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgSotatercept 1.0 mg/kgSotatercept 2.0 mg/kg
AnaemiaBlood and lymphatic system disorders0/70/61/210/351/5
Transfusion reactionInjury, poisoning and procedural complications0/70/60/210/351/5
Blood pressure increasedInvestigations0/70/60/210/351/5
PneumoniaInfections and infestations0/71/61/210/350/5
Subdural haematomaInjury, poisoning and procedural complications0/71/60/210/350/5
Aortic stenosisVascular disorders0/71/60/210/350/5
BronchitisInfections and infestations1/70/60/210/350/5
InfluenzaInfections and infestations1/70/60/210/350/5
Hip fractureInjury, poisoning and procedural complications0/70/62/210/350/5
ColitisGastrointestinal disorders0/70/60/213/350/5
Most frequent other events
Showing 10 of 110
Most frequent other events
EventSotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgSotatercept 1.0 mg/kgSotatercept 2.0 mg/kg
HeadacheNervous system disorders3/71/64/215/351/5
DiarrhoeaGastrointestinal disorders0/72/67/219/352/5
NauseaGastrointestinal disorders0/71/64/218/352/5
Urinary tract infectionInfections and infestations1/70/60/214/352/5
DizzinessNervous system disorders1/72/61/216/352/5
Oedema peripheralGeneral disorders2/72/66/2111/350/5
FallInjury, poisoning and procedural complications0/72/61/211/350/5
FatigueGeneral disorders0/71/66/2111/351/5
ConstipationGastrointestinal disorders0/71/66/213/350/5
DyspnoeaRespiratory, thoracic and mediastinal disorders0/71/66/212/351/5

Baseline characteristics

All randomized participants

Age, Continuous
Age, Continuous(years)Sotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgSotatercept 1.0 mg/kgSotatercept 2.0 mg/kgTotal
Mean67 ± 8.375 ± 6.969 ± 8.071 ± 8.269 ± 13.070 ± 8.4
Age, Customized
Age, Customized(Participants)Sotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgSotatercept 1.0 mg/kgSotatercept 2.0 mg/kgTotal
<65 years3076117
>=65 - <75 years23817232
>=75 years23612225
Sex: Female, Male
Sex: Female, Male(Participants)Sotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgSotatercept 1.0 mg/kgSotatercept 2.0 mg/kgTotal
Female30417428
Male461718146
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgSotatercept 1.0 mg/kgSotatercept 2.0 mg/kgTotal
Hispanic or Latino002002
Not Hispanic or Latino761319449
Unknown or Not Reported00616123
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgSotatercept 1.0 mg/kgSotatercept 2.0 mg/kgTotal
American Indian or Alaska Native000000
Asian000011
Native Hawaiian or Other Pacific Islander000000
Black or African American000101
White761418348
More than one raceNANANANANANA
Unknown or Not Reported00716124
Region of Enrollment
Region of Enrollment(Participants)Sotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgSotatercept 1.0 mg/kgSotatercept 2.0 mg/kgTotal
United States761518450
France00617124
Height
Height(meters)Sotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgSotatercept 1.0 mg/kgSotatercept 2.0 mg/kgTotal
Mean1.70 ± 0.1101.75 ± 0.0541.70 ± 0.0931.68 ± 0.0891.56 ± 0.0431.68 ± 0.095
Weight
Weight(kg)Sotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgSotatercept 1.0 mg/kgSotatercept 2.0 mg/kgTotal
Mean85.3 ± 21.7979.5 ± 13.9077.9 ± 13.9773.5 ± 15.5556.4 ± 7.2575.2 ± 16.14

6 further baseline measures are reported on the registry.

08

Study locations

20 sites
  • Rocky Mountain Cancer Center-Midtown
    Denver, Colorado 80218, United States
  • H. Lee Moffitt Cancer Center and Research Institute
    Tampa, Florida 33612, United States
  • Johns Hopkins
    Baltimore, Maryland 21231, United States
  • Dana-Farber / Harvard Cancer Institute
    Boston, Massachusetts 02215, United States
  • Monter Cancer Center, North Shore LIJ Health Systems
    Lake Success, New York 11042, United States
  • Columbia University Medical Center/New York-Presbyterian Hospital
    New York, New York 10032, United States
  • The Cleveland Clinic Foundation Hematology and Medical Oncology Rm 35
    Cleveland, Ohio 44195, United States
  • Sarah Cannon Research Inst
    Nashville, Tennessee 37203, United States
  • Texas Oncology Round Rock Cancer Center - Round Rock
    Round Rock, Texas 78681, United States
  • University of Texas Health Science Center at San Antonio
    San Antonio, Texas 78229, United States
  • Texas Oncology, P.A. - Tyler
    Tyler, Texas 75702, United States
  • Virginia Oncology Associates
    Norfolk, Virginia 23502, United States
  • Yakima Valley Memorial Hospital/ North Star Lodge
    Yakima, Washington 98902, United States
  • Centre Hospitalier Universitaire d'Avicennes
    Bobigny Cedex, 93009, France
  • Institute Paoli-Calmettes Service Haematology
    Bp 156,, 13273, France
  • CHRU de Lille-Hopital Claude Huriez Service des Maladies du Sang
    Lille, 59037, France
  • CHRU Nantes
    Nantes, 44093, France
  • Hopital Cochin Hematologie
    Paris Cedex 14, 75679, France
  • Centre Henri Becquerel
    Rouen, 79038, France
  • CHU Purpan
    Toulouse, 31059, France
09

References and documents

Publications

  • Komrokji R, Garcia-Manero G, Ades L, Prebet T, Steensma DP, Jurcic JG, Sekeres MA, Berdeja J, Savona MR, Beyne-Rauzy O, Stamatoullas A, DeZern AE, Delaunay J, Borthakur G, Rifkin R, Boyd TE, Laadem A, Vo B, Zhang J, Puccio-Pick M, Attie KM, Fenaux P, List AF. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. Lancet Haematol. 2018 Feb;5(2):e63-e72. doi: 10.1016/S2352-3026(18)30002-4. Epub 2018 Jan 10. PubMed 29331635 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2012 to primary completion in Apr 2018, 65 months.

Results were first posted in Jun 2019, 1 year 1 month after primary completion.

Of 58 industry-sponsored phase 2 interventional studies under Anemia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 40. This study's 65 months is above that.

Counting every sponsor, half of 88 studies reached it within 28 months; a quarter within 16 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2012
First posted
Nov 29, 2012
StartActual
Nov 28, 2012
Primary completionActual
Apr 30, 2018
CompletionActual
Apr 30, 2018
Results first posted
Jun 13, 2019
Last update
Oct 24, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01736683
Responsible party
Sponsor
First posted
Nov 29, 2012
Start date
Nov 28, 2012
Primary completion
Apr 30, 2018
Completion
Apr 30, 2018
Results posted
Jun 13, 2019
Last update
Oct 24, 2022

Study contacts

Rodrigo Ito, MD
study director · Celgene Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotatercept

Start the discussion